Coeptis Therapeutics

01/02/2025

Phase 1 Data on DVX201: study results demonstrate the safety and feasibility of adoptive immunotherapy using allogeneic off-the-shelf NK cells in hospitalized patients with COVID at high risk for progression of disease.

DVX201 is the first allogeneic therapy derived from pooled donor cord blood CD34+ cells that was administered to 9 patients with no dose limiting toxicities, cytokine release syndrome or infusion toxicities.

ICYMI, read more: https://bit.ly/4hGGCnS

12/30/2024

Coeptis is developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration leading medical researchers. Discover the science behind our CAR therapy in development: https://www.youtube.com/watch?v=HCEvs3mPWak

Coeptis Therapeutics' SNAP-CAR therapy is a universal cell-based treatment designed to overcome many of the challenges and limitations associated with existi...

12/27/2024

Coeptis recently announced the official launch of Coeptis Technologies, a new division aimed at diversifying and enhancing the company's growth potential.

This strategic move underscores Coeptis' commitment to maximizing shareholder value and capitalizing on high-growth opportunities across different sectors. In case you missed the announcement, dive into the press release here: https://bit.ly/4gO5w3D

12/24/2024

With the holidays upon us, Coeptis Therapeutics extends warm wishes to our team, partners, and stakeholders. Thank you for being an integral part of our journey. We look forward to continued collaboration and breakthroughs in the year ahead.

12/18/2024

Joshua Hill, MD, associate professor and physician at Fred Hutch Cancer Center and corresponding author of the Phase 1 study evaluating DVX201, an allogeneic natural killer (NK) cell therapy, for the treatment of patients hospitalized with COVID-19 comments:

"Despite advances in treatment and prevention strategies for SARS-CoV-2, COVID-19 still results in substantial morbidity in certain patient populations underscoring the ongoing need for additional therapeutic options, particularly among immune compromised individuals.

Although the study was not designed to assess efficacy, our findings demonstrate the safety and potential utility of NK cell therapy as a complementary therapeutic strategy for viral infections in high-risk patients."

To access the full publication in Molecular Therapy Methods and Clinical Development, please visit: https://bit.ly/4i6P8N2

12/11/2024

Phase 1 Data on DVX201 for COVID-19: Results from the clinical trial demonstrated the safety and feasibility of DVX201 as a potential treatment for patients with active SARS-CoV-2 infections.

The following key findings are highlighted:

• First Demonstration of Safety: This is the first known study to demonstrate the safety of adoptive immunotherapy with allogeneic, off-the-shelf NK cells in patients with active COVID-19, especially those at high risk for disease progression.
• Innovative NK Cell Therapy: DVX201 is the first allogeneic NK cell adoptive immunotherapy used clinically that is derived from pooled donor cord blood CD34+ cells, offering a scalable, consistent, and cost-effective solution to barriers in the allogeneic cell therapy space.
• No Adverse Events: DVX201 infusions were safe and well-tolerated, with no treatment-related adverse events, including no cytokine release syndrome (CRS).

In case you missed the news, read the press release here: https://bit.ly/4hGGCnS

12/10/2024

Coeptis Therapeutics is committed to innovation, and this acquisition of NexGenAI Affiliates Network is a testament to that commitment.

By integrating AI-powered solutions and RPA tools, we're not only improving our own operations but also creating new opportunities for growth in the biotech, pharmaceutical, and MLM industries.

Learn more in our press release here: https://bit.ly/3OCRGVC

12/05/2024

Coeptis Therapeutics CEO, Dave Mehalick, on the Future of Cell Therapy with Snap-Car.

“Our vision for SNAP-CAR goes beyond the current cell therapy landscape, our approach is two-fold. We’re combining innovative cell engineering technology with an established, allogeneic cell generation platform to enable a truly universal CAR-therapy.

The value proposition for the cell therapy market isn’t based on where the market sits today. Rather it centers on its transformative potential to address unmet medical needs, improve patient outcomes, and ultimately reshape the future of healthcare.”

https://coeptistx.com/

12/04/2024

We're pleased to share that Coeptis Therapeutics has executed a Binding Letter of Intent to acquire NexGenAI Affiliates Network. This acquisition will bring AI-powered marketing solutions and robotic process automation (RPA) capabilities to Coeptis, enhancing our operational efficiency and driving innovation. Read more in the press release here: https://bit.ly/3OCRGVC

12/03/2024

Coeptis Therapeutics (Nasdaq: COEP) Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries.

Read the press release here: https://bit.ly/3OCRGVC

11/26/2024

Meet Dan Yerace, Vice President of Operations at Coeptis Therapeutics, a key member of our leadership team, passionately driving forward the development of our universal SNAP-CAR NK therapy.

“The excitement around SNAP-CAR continues to grow! By embracing innovations in manufacturing processes, such as automation and scalable production methods, this is helping reduce costs and improving efficiency of cell therapy development. In turn, hopefully making these therapies more accessible to patients in need.”

Learn more in the video below. https://bit.ly/477Xa3d

11/18/2024

Coeptis Therapeutics is excited to be at the Donor Selection & Cell Source Summit in San Diego! Our CSO/CMO, Colleen Delaney, MD, MSc is presenting how Coeptis is focused on delivering off-the-shelf universal allogeneic therapies, with the goal of revolutionizing cell therapy by dramatically lowering treatment costs and improving access to life-saving therapies for patients with cancer and other critical disease.